The VIC Fellows Program provides an opportunity for individuals with relevant expertise and interest to learn how to identify and evaluate promising innovations from global sources. We are pleased to highlight the...
The University of California San Francisco (UCSF) Health Awards named CardioWise, Inc. as a Rising Star in the Clinical Diagnostic Tool category. The awards highlight the health tech industry, showcasing the best new...
Please describe your background/career path that led you to your current role. I received my Doctorate in Toxicology and Molecular Biology from Washington State University and have spent the majority of my career in...
CardioWise™ is commercializing patented, Cardiac Computed Tomography (CT) machine learning analysis software, SQuEEZ™, which produces a quantified image model of human heart function. Fayetteville, AR - The University...
Mississauga, Ontario – Cymat Technologies Ltd. (TSXV: CYM) (the "Company" or "Cymat") is pleased to announce that, in collaboration with design partner Tesseract Structural Innovations Inc. (“Tesseract”), Cymat has...
Leading expert in alopecia, Dr. Brett King brings deep academic insight, broad preclinical and clinical expertise and drug development experience to help BiologicsMD advance its innovative hair and bone therapies New...
The VIC Fellows Program provides an opportunity for individuals with relevant expertise and interest to learn how to identify and evaluate promising innovations from global sources. We are pleased to highlight the...
Albuquerque. NM, Nob Hill Therapeutics announced today the appointment of Craig Davies-Cutting, PhD, as Vice President of Research and Development. Dr. Davies-Cutting will contribute his extensive respiratory product...
Instrument Will Enable Near Real-Time Detection of Biomarkers and Drug Targets Fayetteville, AR - VIC Foundry, in collaboration with the University of Buffalo, has been awarded a $259,000 grant from the National...
Albuquerque, NM - Nob Hill Therapeutics (NHT), a VIC Technology Venture Development portfolio company, announced today that it has received an HHS phase II grant (up to $1.73M) to develop an inhaled therapy to treat...
FEATURED RESOURCES
